← Human Trials & Peer-Reviewed Studies
Association between renal function and fracture incidence during treatment with teriparatide or alendronate: an exploratory subgroup analysis of the Japanese Osteoporosis Intervention Trial-05
Plain-language guide to PMID 39343826 (2024): randomized controlled trial study of Teriparatide.
Key Facts
- PMID
- 39343826
- Journal
- Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
- Year
- 2024
- Study type
- Randomized Controlled Trial
- Authors
- Takeuchi Y et al. (6 authors)
- DOI
- 10.1007/s00198-024-07260-9
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Teriparatide, published as a randomized controlled trial.
This is an exploratory subgroup analysis according to chronic kidney disease (CKD) status at baseline.
Why It Was Studied
The association of renal function with fracture incidence during teriparatide or alendronate treatment in elderly Japanese women was examined.
Fracture incidence differed by fracture type, renal function, and treatment protocol.
Who Took Part
The age groups tagged for this paper are older adults and people over 80, women only.
Participants received sequential therapy with TPTD for 72 weeks, followed by ALN for 48 weeks (TPTD-ALN group, N = 483) or ALN monotherapy for 120 weeks (ALN group, N = 496).
How the Study Was Run
The design is described as randomized.
Random assignment meant chance, not the researchers, decided who got Teriparatide and who got the comparison, which limits bias.
The methods mention a period of 72 weeks.
Incidences of vertebral fractures including morphometric fractures, non-vertebral fractures, and all fractures were evaluated during follow-up.
What Was Measured
Topics PubMed links to this paper include Alendronate, Bone Density Conservation Agents, Teriparatide, Osteoporotic Fractures, Spinal Fractures, Glomerular Filtration Rate and Incidence.
The authors tagged it with the keywords Chronic kidney disease, Fracture incidence and Osteoporosis.
What This Means in Plain Language
The paper is a randomized study of Teriparatide over 72 weeks.
Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2024 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.
More context: the Teriparatide compound page, all human trials.
Our Notes on the Compound
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.